CA2539325C - Consensus/ancestral immunogens - Google Patents

Consensus/ancestral immunogens Download PDF

Info

Publication number
CA2539325C
CA2539325C CA2539325A CA2539325A CA2539325C CA 2539325 C CA2539325 C CA 2539325C CA 2539325 A CA2539325 A CA 2539325A CA 2539325 A CA2539325 A CA 2539325A CA 2539325 C CA2539325 C CA 2539325C
Authority
CA
Canada
Prior art keywords
nucleic acid
nucleotide sequence
set forth
con
subtype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2539325A
Other languages
English (en)
French (fr)
Other versions
CA2539325A1 (en
Inventor
Bette T. Korber
Beatrice H. Hahn
George M. Shaw
Denise Kothe
Ying Ying Li
Julie Decker
Barton F. Haynes
Feng Gao
Hua-Xin Liao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
University of California San Diego UCSD
Duke University
Original Assignee
UAB Research Foundation
University of California San Diego UCSD
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation, University of California San Diego UCSD, Duke University filed Critical UAB Research Foundation
Priority to CA2918585A priority Critical patent/CA2918585C/en
Publication of CA2539325A1 publication Critical patent/CA2539325A1/en
Application granted granted Critical
Publication of CA2539325C publication Critical patent/CA2539325C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C07K16/4225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig against anti-HIV Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2539325A 2003-09-17 2004-09-17 Consensus/ancestral immunogens Expired - Fee Related CA2539325C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2918585A CA2918585C (en) 2003-09-17 2004-09-17 Consensus/ancestral immunogens

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50346003P 2003-09-17 2003-09-17
US60/503,460 2003-09-17
US60472204P 2004-08-27 2004-08-27
US60/604,722 2004-08-27
PCT/US2004/030397 WO2005028625A2 (en) 2003-09-17 2004-09-17 Consensus/ancestral immunogens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2918585A Division CA2918585C (en) 2003-09-17 2004-09-17 Consensus/ancestral immunogens

Publications (2)

Publication Number Publication Date
CA2539325A1 CA2539325A1 (en) 2005-03-31
CA2539325C true CA2539325C (en) 2016-03-22

Family

ID=34381074

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2539325A Expired - Fee Related CA2539325C (en) 2003-09-17 2004-09-17 Consensus/ancestral immunogens
CA2918585A Expired - Fee Related CA2918585C (en) 2003-09-17 2004-09-17 Consensus/ancestral immunogens

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2918585A Expired - Fee Related CA2918585C (en) 2003-09-17 2004-09-17 Consensus/ancestral immunogens

Country Status (10)

Country Link
US (3) US8071107B2 (enExample)
EP (2) EP1667714B1 (enExample)
JP (3) JP4773352B2 (enExample)
KR (2) KR20120086379A (enExample)
CN (2) CN1852734B (enExample)
AU (1) AU2004274937B9 (enExample)
BR (1) BRPI0414443A (enExample)
CA (2) CA2539325C (enExample)
IL (3) IL174380A0 (enExample)
WO (1) WO2005028625A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1307130A4 (en) 2000-02-04 2005-01-12 Beth Israel Hospital VACCINE AGAINST THE VIRUS OF HUMAN IMMUNODEFICIENCY
WO2002024149A2 (en) 2000-09-22 2002-03-28 Duke University Immunogen comprising ligand bound hiv envelpe protein
US7033593B2 (en) 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
US8048431B2 (en) * 2003-09-17 2011-11-01 Duke University Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
US8071107B2 (en) 2003-09-17 2011-12-06 Duke University Nucleic acids encoding modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins
EP2295974A1 (en) 2004-09-08 2011-03-16 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Compositions and methods for the detection of HIV-1/HIV-2 infection
WO2007024941A2 (en) 2005-08-23 2007-03-01 The Regents Of The University Of California Polyvalent vaccine
US7951377B2 (en) 2005-08-23 2011-05-31 Los Alamos National Security, Llc Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
AP3642A (en) * 2006-03-10 2016-03-16 Peptcell Ltd Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof
ES2388443T3 (es) 2006-03-29 2012-10-15 Dana-Farber Cancer Institute, Inc. Métodos y composiciones para inducir una respuesta inmune frente a VIH y modelos para ensayo
JP2009539353A (ja) * 2006-06-02 2009-11-19 インターナショナル エイズ バクシーン イニシアティブ Ｈｉｖ−１クレイドａのコンセンサス配列、抗原及びトランス遺伝子
AU2015234338C1 (en) * 2006-07-28 2017-07-20 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
EP2708549B1 (en) * 2006-07-28 2016-07-06 The Trustees Of The University Of Pennsylvania Improved vaccines for targetting telomerase
JP2010530356A (ja) * 2007-03-27 2010-09-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 急性伝染ｈｉｖエンベロープ・サイン
CN102282175B (zh) 2008-11-18 2015-09-30 贝斯以色列护理医疗中心 具有改进的细胞免疫原性的抗病毒疫苗
EP2539365A4 (en) * 2010-02-25 2015-03-25 Univ Duke METHOD FOR PRODUCING PROTECTION ANTIBODIES AGAINST HIV-1
WO2011109104A2 (en) * 2010-03-03 2011-09-09 The Uab Research Foundation Molecular clone of hiv-1
WO2012047267A2 (en) * 2010-09-28 2012-04-12 Duke University Polyvalent immunogen
EP2492279A1 (en) * 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
WO2013006688A2 (en) 2011-07-05 2013-01-10 Duke University N-terminal deleted gp120 immunogens
CA2850745C (en) 2011-10-03 2022-12-13 Duke University Vaccine
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
ES2718899T3 (es) 2012-03-02 2019-07-05 Us Gov Health & Human Services Método para modificar la jerarquía de inmunodominio de gag del VIH mediante una vacuna de ADN que expresa regiones conservadas
SG11201500439RA (en) * 2012-07-24 2015-02-27 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
KR101826536B1 (ko) 2012-08-07 2018-02-07 현대자동차 주식회사 차량의 아이들 스톱 제어 방법 및 장치
WO2014151687A2 (en) 2013-03-15 2014-09-25 University Of Massachusetts Compositions and methods to treat aids
EP3058065B1 (en) * 2013-10-16 2018-05-02 New England Biolabs, Inc. Reverse transcriptase with enhanced properties
MA40783A (fr) * 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
WO2017007646A1 (en) * 2015-07-07 2017-01-12 International Aids Vaccine Initiative Hiv-1 clade c envelope glycoproteins
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
US11246920B2 (en) 2016-03-03 2022-02-15 Duke University Compositions and methods for inducing HIV-1 antibodies
EA201990715A1 (ru) * 2016-09-15 2019-08-30 Янссен Вэксинс Энд Превеншн Б.В. Стабилизирующие тример мутации белка оболочки hiv
US10828363B1 (en) * 2016-09-16 2020-11-10 The Trustees Of The University Of Pennsylvania Extreme polyvalency induces potent cross-clade cellular and humoral responses in rabbits and non-human primates
EP3519428A4 (en) 2016-10-03 2020-07-08 Duke University METHODS OF IDENTIFYING IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS
WO2018075559A1 (en) 2016-10-17 2018-04-26 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
CA3114870A1 (en) 2018-10-01 2020-04-09 Duke University Hiv-1 envelope stabilizing mutations
GB201816873D0 (en) * 2018-10-17 2018-11-28 Imperial Innovations Ltd Fusion protein
CN120775062A (zh) 2019-07-16 2025-10-14 吉利德科学公司 Hiv疫苗及其制备和使用方法
CA3161633A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines
AU2022207422A1 (en) 2021-01-14 2023-07-27 Gilead Sciences, Inc. Hiv vaccines and methods of using
CA3246969A1 (en) * 2022-03-31 2023-10-05 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. IMMUNOGENS AND HIV VACCINE COMPOSITIONS
WO2025072797A2 (en) * 2023-09-27 2025-04-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Immunogens and vaccine compositions against hiv

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US20030096778A1 (en) * 2002-06-13 2003-05-22 Shiver John W Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
AU4529401A (en) 2000-02-18 2001-08-27 Univ Washington Aids ancestral viruses and vaccines
US7655774B2 (en) 2000-02-18 2010-02-02 University Of Washington Ancestral and COT viral sequences, proteins and immunogenic compositions
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
WO2002024149A2 (en) 2000-09-22 2002-03-28 Duke University Immunogen comprising ligand bound hiv envelpe protein
US7172761B2 (en) 2001-11-07 2007-02-06 Duke University Polyvalent immunogen
US8071107B2 (en) 2003-09-17 2011-12-06 Duke University Nucleic acids encoding modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins
US8048431B2 (en) 2003-09-17 2011-11-01 Duke University Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
HRP20040589B1 (en) 2004-06-28 2011-07-31 Biljan Marijan The stand for garment hangers with a built-in counter

Also Published As

Publication number Publication date
JP2007505624A (ja) 2007-03-15
US20120087938A1 (en) 2012-04-12
CA2918585A1 (en) 2005-03-31
CN1852734A (zh) 2006-10-25
JP6165612B2 (ja) 2017-07-19
AU2004274937B2 (en) 2011-03-24
US10946090B2 (en) 2021-03-16
KR20120086379A (ko) 2012-08-02
BRPI0414443A (pt) 2006-11-21
IL230011A0 (en) 2014-01-30
AU2004274937A1 (en) 2005-03-31
EP2371387A3 (en) 2012-01-25
EP1667714A2 (en) 2006-06-14
JP2011136997A (ja) 2011-07-14
CA2918585C (en) 2019-05-21
HK1097446A1 (en) 2007-06-29
JP2014079250A (ja) 2014-05-08
AU2004274937B9 (en) 2011-04-14
US20180296665A1 (en) 2018-10-18
CN102010463A (zh) 2011-04-13
KR20070028291A (ko) 2007-03-12
CN1852734B (zh) 2010-12-01
EP2371387A2 (en) 2011-10-05
EP1667714A4 (en) 2008-09-24
US20070178562A1 (en) 2007-08-02
JP4773352B2 (ja) 2011-09-14
CA2539325A1 (en) 2005-03-31
EP1667714B1 (en) 2018-01-03
IL202249A (en) 2015-08-31
IL174380A0 (en) 2006-08-01
WO2005028625A3 (en) 2005-06-02
AU2004274937A2 (en) 2005-03-31
US9844589B2 (en) 2017-12-19
WO2005028625A2 (en) 2005-03-31
US8071107B2 (en) 2011-12-06

Similar Documents

Publication Publication Date Title
US10946090B2 (en) Consensus/ancestral immunogens
US8048431B2 (en) Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
US7666427B2 (en) HIV vaccines based on Env of multiple clades of HIV
Kim et al. Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies
EP1038001B1 (en) Constitutive expression of non-infectious hiv-like particles
Gorny et al. Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins
US20120225083A1 (en) Viral polypeptides and methods
AU2017200429B2 (en) Consensus/Ancestral Immunogens
RU2654673C2 (ru) Мутантные лентивирусные белки env и их применение в качестве лекарственных средств
Palker et al. The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope
Robert-Guroff et al. Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization
MXPA06003076A (en) Consensus/ancestral immunogens
HK1097446B (en) Consensus/ancestral immunogens
HK1155758A (en) Consensus/ancestral immunogens
US20050112138A1 (en) Aids vaccines
Infectivity Antibodies Generated in Cats by

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220920